Whether peptidases present in vascular cells can activate prodrugs active on vascular cells has been tested with 2 potential latent ligands of the histamine H 1 receptor (H 1 R). First, a peptide consisting of the antihistamine cetirizine (CTZ) condensed at the N-terminus of ε-aminocaproyl-bradykinin (εACA-BK) was evaluated for an antihistamine activity that could be revealed by degradation of the peptide part of the molecule. CTZ-εACA-BK had a submicromolar affinity for the BK B 2 receptor (B 2 R; IC 50 of 590 nM, [ The human umbilical vein contractility assay responded to L-alanyl-histamine (EC 50 54.7 µM), but the APN inhibitor amastatin massively (17-fold) reduced its apparent potency. Amastatin did not influence the potency of histamine as a contractile agent. One of the 2 tested latent H 1 R ligands, Lalanyl-histamine, supported the feasibility of pro-drug activation by vascular ectopeptidases.
Introduction
Peptidases expressed in vascular tissue are important modulators of the pharmacology of vasoactive peptides. Angiotensin converting enzyme (ACE), expressed in endothelial cells, hydrolyses both angiotensin I and bradykinin (BK). In the first case, this is a physiological activation, as the product angiotensin II is the optimal agonist of the AT 1 receptors, while the second reaction leads to BK inactivation [1] . However, we reported lately that the peptide Met-Lys-bradykinin-Ser-Ser is paradoxically activated by its reaction with ACE, that frees the BK C-terminal sequence needed to activate the cognate B 2 receptor (B 2 R) [2] . The modulatory role of vascular aminopeptidase N (APN) has also been illustrated, as the blockade of this ectopeptidase, expressed in vascular smooth muscle, potentiates such peptides as Lys-des-Arg 9 -BK (the optimal agonist of human and rabbit BK B 1 receptor), some peptide antagonists of B 1 receptors and angiotensin III [3, 4] .
BK is a fragile peptide inactivated rapidly both in the extracellular compartment and in endosomes.
The nonapeptide BK, via its preformed, phosphorylable and G protein coupled B 2 R, is an excellent example of an agonist submitted to endocytosis and degradation [5] . Endosomal BK degradation obligatorily precedes the dissociation of β-arrestins from the B 2 R and receptor recycling to the cell surface, as shown by several inactivation-resistant B 2 R agonists that promote the persistence of this intracellular complex for at least 12 h and prolonged signaling [6, 7] . Fluorophore conjugated analogs (carboxyfluorescein-or AlexaFluor-350-ε-aminocaproyl-BK) model the intracellular inactivation of the kinin, notably because the inhibitor of the proton pump V-ATPase, bafilomycin A1, prevents the time-dependent disappearance of the fluorescent peptides in endosomes of B 2 Rexpressing cells [8, 9] . Free carboxyfluorescein is also released into the cytosol as a function of time in these cells, suggesting a particular strategy to release a drug cargo from BK conjugates.
A possible manner to generate diversity in drug candidates is to design ligands for more than one pharmacological target; for instance omapatrilat has been designed to block both BK-destroying peptidases ACE and neutral endopeptidase (NEP) with nanololar affinities [10] . A further step could concern ligands that successively bind to one target, and then to another upon metabolic alteration.
Among several carboxylic acids that have been condensed with ε-aminocaproyl-BK, we recently reported the antihistamine drug cetirizine (Fig. 1) [9] . As other N-terminally extended analogs of BK, cetirizine-ε-aminocaproyl-bradykinin (CTZ-εACA-BK) is a full agonist the B 2 R, but with a low affinity [9] . A similarly designed analog, carboxyfluorescein-εACA-BK, has an affinity for ACE that is identical to that of BK [8] . Testing the concept of a pro-drug activable by vascular tissue metabolism may be based on CTZ-εACA-BK because cetirizine has a high persistence of its binding to histamine H 1 receptor (H 1 R) [11] . Conjugated cetirizine, with its carboxylic acid function engaged in an amide bond, is predicted to have a low or no affinity for the H 1 R. An alternative prodrug potentially activated by a vasopeptidase was based on the agonist histamine condensed with alanine: L-alanyl-histamine ( Fig. 1 ) was tested as a latent H 1 R agonist activable by aminopeptidase N (APN, CD13, EC 3.4.11.2), on the model of the standard chromogenic substrate of APN, L-Alap-nitroanilide [12] . In addition to molecular studies based on recombinant B 2 R and H 1 R, we exploited the human umbilical vein contractility assay naturally expressing these two receptor types that mediate important contractile responses [13, 14] . This vein also expresses ACE [2, 15] . The ectopeptidase APN is present in the vascular smooth muscle cells of the umbilical artery [3, 4] and at least in the endothelium of the umbilical vein [16, 17] .
Materials and methods

Synthesis of L-alanyl-histamine
The synthesis of L-alanyl-histamine (4-[β-(α-alanylamido)-ethyl]-1-H-imidazole (2-amino-N-[2-(1H-imidazol-4-yl)ethyl]-(2S)-propanamide) has been previously reported [18] based on Boc-L-Ala and tritylsulfenyl-histamine using the diisopropyl-carbodiimide coupling reagent. This method was slightly modified using histamine dihydrochloride and the BOP coupling reagent.
Diisopropylethylamine (4 mmol, 697 µl) was added to the stirred suspension of Boc-Ala (1 mmol, 189.2 mg) (Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP, 1 mmol, 442.3 mg), and histamine dihydrocloride (1 mmol, 184.1 mg) in 25 ml acetonitrile. The mixture was stirred overnight at room temperature. The solvent was removed in vacuum and the oily residue was dissolved in 75 mL ethyl acetate. The organic phase was extracted with 5 % KHSO 4 (3 × 10 ml), brine (10 ml), 5 % NaHCO 3 (3 × 10 ml), brine (10 ml). The organic phase was dried over anhydrous Na 2 SO 4 . The solvent was evaporated affording a white powder. The crude product can be used for the Boc-deprotection without further purification or could be purified by preparative HPLC on a C18 column (131 mg, 46.4 %), (2- 
The N a -Boc-group was cleaved according to the classical deprotection procedure. The Boccompound (141.2 mg, 0.5 mmol) was dissolved in 25 % TFA in dichloromethane (DCM, 25 ml).
After 30 min, the solution was concentrated under reduced pressure at room temperature and the residue was lyophilized from 15 ml of H 2 O to give the crude product as a trifluoroacetic acid (TFA) [PMSF], and 1 µM captopril). 0.5 ml of this buffer was left in each cell well, to which were optionally added cold competitors and the radioligand. After 90 min incubation at 0°C, cell wells were washed 3 times with 1 ml of ice-cold PBS. The wells' supernatants were discarded and the cells were dissolved in 1 ml NaOH 0.1 N. This suspension was transferred in a scintillation vial containing 7 ml of Ecolite Plus and counted for radioactivity.
The binding assays were applied to construct saturation curves for both radioligands by varying the concentration of each radioligand. Non-specific binding was obtained in matched cell wells cotreated with unlabeled BK (1 µM) or pyrilamine (1 µM) and subtracted from total binding to evaluate specific binding. A second series of experiments involved the competition of a fixed concentration of each radioligand with a panel of unlabeled drugs used at variable concentrations to evaluate their affinity at each receptor from binding competition curves.
Radioreceptor assay
A variation of the competition protocol (radioreceptor assay) was used to evidence the possible 
β-arrestin 1 condensation assay
CHO cells were co-transfected with a vector encoding β-arrestin 1 -cherry (kind gift from Dr. Martin
Beaulieu, Université Laval, Quebec City, Canada) and another one encoding one of the receptors under study. The cells were stimulated with drugs (37°C, 30 min) and the red epifluorescence was then observed. The goal of the experiment was to monitor the endosomal condensation of the β-arrestin (as in [8] ) in response to a given compound: if the condensation occurs, the ligand is an agonist. If no condensation is noted, the agent may not bind the studied type of receptor or may be an antagonist of this receptor.
Contractility assay
The anonymous use of human umbilical cords obtained after elective caesarean section deliveries was approved by a local institutional research ethics board. The preparation of the umbilical vein rings was described elsewhere [20] . This vein is a suitable contractile bioassay for both the B 2 R and H 1 R [13, 14] . After a 2.5-h equilibration period during which tissues were periodically washed with fresh Krebs buffer, tissues were randomly assigned to one of the experimental groups in several protocols further described in Results.
Immunofluorescence of peptidases in the human umbilical vein
The conversion of the latent H 1 R ligands in the venous contractility assay described above is dependent on the presence of peptidases in the vascular structure, minimally ACE and APN. Fiveµm-thick paraffin tissue section of the human umbilical vein in situ were rehydrated and processed for the immunofluorescence of ACE using anti-ACE polyclonal antibodies C28 (dilution 1:50)
raised against the C-terminal sequence of human ACE [21] (gift from Prof. P. Corvol, INSERM U36, Paris, France) and of APN (CD13) using the mouse monoclonal anti-CD13 antibodies (BD Pharmingen, clone WM-15, dilution 1:50) (general immunofluorescence methods as in Morissette et al., [22] ). Other sections were stained using anti-α-actin monoclonal antibodies (dilution 1:100, clone 1A4, Sigma-Aldrich) to identify vascular smooth muscle. Staining was revealed using the appropriate AlexaFluor-conjugated secondary antibodies and sections were observed (epifluorescence, 100 ×).
Data analysis
Numerical values are reported as means ± s.e.m. The data from competition assays involving radioligand binding were fitted by nonlinear regression to a one-site competition equation to derive IC 50 values (Prism 5.0, GraphPad Software Inc., San Diego, CA). The contractility concentrationeffect data were analyzed with Prism (sigmoidal dose-response curve with variable slope) to obtain
EC 50 values and their 95% confidence limits (C.L.). χ 2 statistics (comparison of frequencies) was used to determine qualitative drug effect on the endosomal labeling by recombinant β-arrestin 1 , the categories being: presence or absence of robust labeling.
Results
Radioligand binding studies
As judged from the results of radioligand binding assays, CHO cells were found suitable to transiently express both recombinant human histamine H 1 R and the tagged construction myc-B 2 R (Fig. 2) (Fig. 2D) .
β-arrestin 1 condensation in CHO cells
An (Fig. 2D ) effectively condensed the arrestin at the level of multiple granular structures located in the cytosol (Fig. 3) . Histamine was inactive in this respect in cells that expressed myc-B 2 R but was active in those expressing H 1 R (the frequency of the response being significant relative to control, but smaller than that achieved with BK stimulation of myc-B 2 R). The histamine H 1 R did not mediate arrestin condensation in response to either BK sequences (Fig. 3) , either because BK has no affinity at this receptor (as proven by Fig. 2B ) or because the CTZ conjugate is an antagonist ligand of the H 1 R.
Metabolic activation of CTZ-εACA-BK in the human umbilical vein
HEK 293 cells that stably express the fluorescent receptor B 2 R-GFP exhibit the endocytosis of this construction in response to CTZ-εACA-BK (5 µM) and this translocation was prevented by treatment with LF 16-0687 [9] . Whether the intracellular metabolism of the conjugated peptide in endosomes releases free cetirizine has been tested using the competition assay (binding of 2 nM (Fig. 2C) , was not rendered more active by preincubation with cells that expressed B 2 R-GFP (Fig. 3A) . Alternatively, the latent Tables 1 and 2 ). Thus, based on the lack of gain of function, there is no evidence that CTZ-εACA-BK can release free cetirizine in biological environments.
Pharmacology and metabolic activation of L-alanyl-histamine
When used at concentrations up to 300 µM, L-alanyl-histamine did not compete intensely enough with for [ In the human umbilical vein contractility assay, L-alanyl-histamine, is a contractile agent less potent than histamine (Fig. 5B , numerical parameters in Table 1 ). Pretreatment of tissue with the APN inhibitor amastatin had contrasting effects on the apparent potency of the 2 agonists: it did not affect that of histamine, but reduced 17-fold that of L-alanyl-histamine, supporting that the latter derivative is a pro-drug metabolically releasing histamine in situ.
It was hypothesized that peptidases expressed in blood vessels, and specifically in the robust contractility assay based on the human umbilical vein, would release H 1 R ligands from peptide-like pro-drugs. In the present study, the previously reported conjugate CTZ-εACA-BK [9] was further characterized as a dual ligand of both B 2 R and H 1 R based on radioligand competition assays (Fig.   2C, D) , and categorized as an agonist and probable antagonist of these respective receptors, based on the arrestin condensation assay (Fig. 3) . As the peptide BK is metabolized via several degradative pathways in endosomes following B 2 R-mediated internalization [23] , the endosomal release of cetirizine from a prodrug that is a B 2 R agonist was an alternate possibility. The direct affinity for the H 1 R in a binding assay conducted at ice temperature was unexpected and constituted a first limitation of the approach, because the metabolic release of free cetirizine would have increased its potency by about 20-fold only at the H 1 R (compare the relative potencies in Fig. 2C ). Thus, despite the facts that the fluorescent conjugate CF-εACA-BK binds to ACE with an affinity equal to BK and that this peptide apparently releases free carboxyfluorescein after endocytosis [8] , metabolic release of free cetirizine from the analog peptide CTZ-εACA-BK was not pharmacologically detected under the forms of a potent antagonism of histamine or of a competitor for the binding of [ efficient APN substrates, such as L-Ala-p-nitroanilide (see Introduction). As predicted, L-alanylhistamine has practically no affinity for the H 1 R (Fig. 5A ), but naturally expressed APN released histamine from it (detected as a contractile agent in the umbilical vein, Fig. 5B ). The APN inhibitor amastatin abated the conversion of L-alanyl-histamine into a H 1 R stimulant, consistent with the metabolic activation model. Thus, the potency of L-alanyl-histamine as a contractile agent in the isolated vein (Fig. 5B) is determined by the enzymatic velocity of the APN, the diffusion rates of the pro-drug into, and that of the produced histamine out of the tissue and, possibly, by histamine degradation within the tissue (the general problem of non-equilibrium pharmacological effects on isolated tissues is discussed elsewhere [14] ).
The interest of activation of pro-drugs by ectopeptidases will essentially depend on the distribution of these enzymes in tissues. We have previously shown the activation of a B 2 R agonist from the peptide Met-Lys-BK-Ser-Ser by ACE [2] . ACE is essentially endothelial (Supplementary Fig. 1 ), renal and plasmatic and there may be valid reasons for locally stimulating the endothelial B 2 Rs with selectivity, e.g., elicit vasodilation without stimulation of afferent nerve terminals where B 2 Rs are also present. APN is rather widely expressed [24] , but is overexpressed during tumoral angiogenesis and in certain tumors [16, 17, 25, 26] , raising for instance the possibility to use L-alanyl-histamine as a vasodilator adjuvant to deliver chemotherapeutic agents.
One of the two tested latent H 1 R ligands, L-alanyl-histamine, supported the feasibility of pro-drug activation by vascular ectopeptidases. 
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Supplementary Results: Lack of evidence for the metabolic activation of CTZ-εACA-BK in the isolated human umbilical vein
The contractility assay exploited in the present studies is based on the human umbilical vein. ACE was identified essentially at the luminal surface of venous tissue section (immunofluorescence, Supplementary Fig. 1 ) consistent with the endothelial expression of this ectopeptidase.
Aminopeptidase N seemed expressed by both the endothelium, as previously reported for cultured human umbilical vein endothelial cells [16] , and the smooth muscle cells, although generally less intensely in the latter case (the muscle cell layer can be identified by comparison with cells positive for α-actin, Supplementary Fig. 1 ).
The fresh rings of umbilical veins were allowed 2.5 h of equilibration post-mounting in organ tissues baths. Protocol I (schematic representation in Supplementary Fig. 2A ) was designed to verify that authentic cetirizine (25 nM) antagonized histamine-induced contraction (concentration-effect curve constructed at time 4 h) without affecting that induced by BK (curve constructed at 3 h). This prediction was fully verified, the apparent potency of histamine being reduced 50-fold without a significant loss of the extrapolated maximal effect ( Supplementary Fig. 2B , C; EC 50 and E max statistics reported in Supplementary Table 1) .
Whether CTZ-εACA-BK could antagonize histamine in the vein contractility was then tested (Protocol II, schematically represented in Supplementary Fig. 3A ; results in Supplementary Fig. 3B and Supplementary Table 2 DMSO (7) cetirizine 25 nM (7) treatment at 2.5 h
B. Supplementary Fig. 2 A. Human umbilical vein contractility: DMSO (7) cetirizine 25 nM (7) treatment at 2.5 h A. Supplementary Fig. 3 Protocol II histamine 4 h C. Supplementary Fig. 4 2.5 h LF 16 Supplementary Fig. 1A . B.
Cumulative concentration-effect of histamine constructed at time 4 h as a function of successive pretreatments (presentation as in Supplementary Fig. 2B ). C. In experiments reported in panel B, the results of the maximal histamine-induced contraction (E max , in g) did not differ between groups, but that of a kinin measured at 3. 
